Divalproex Sodium Tablet, Delayed Release
FDA Recall NDC 69452-433

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Divalproex Sodium (NDC 69452-433). A significant event, classified as Class II, was initiated on Jun 26, 2026 by Bionpharma Inc.. The reported reason for this action was: "Presence of Foreign Tablets/Capsules"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

June 2026 Class II Recall: Presence of Foreign Tablets/Capsules

Recall Number
Class II Ongoing
Reason for Recall
Presence of Foreign Tablets/Capsules
Initiated
Jun 26, 2026
Reported
Jul 29, 2026
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
99316
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Bionpharma Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide.
Product Description
Divalproex Sodium Delayed-Release Tablets, USP, 500 mg, 500 Tablets bottles, Rx only, Distributed by: Bionpharma Inc., Princeton, NJ 08540, Made in India, NDC 69452-435-30.
Batch or Lot Expiration Information
Lot# 704C003, Exp. 12/31/2028
Affected Packages Involved in this Recall
69452-433-13Product
69452-433-20Product
69452-433-30Product
69452-434-13Product
69452-434-20Product
69452-434-30Product
69452-435-13Product
69452-435-20Product
69452-435-30Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.